Skip to main content
RIBOMIC Inc. logo

RIBOMIC Inc. — Investor Relations & Filings

Ticker · 4591 ISIN · JP3974850004 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2024-11-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4591

About RIBOMIC Inc.

https://www.ribomic.com/eng/

RIBOMIC Inc. is a biopharmaceutical company engaged in the discovery and development of novel molecular-targeted therapeutics using its proprietary RNA aptamer technology. The company's core drug discovery platform, the RiboART System (Ribomic Aptamer Refined Therapeutics System), enables the creation of aptamers that bind to target molecules with high affinity and specificity. RIBOMIC's development pipeline focuses on addressing significant unmet medical needs in various therapeutic areas. Key clinical programs include potential treatments for ophthalmic conditions, such as wet age-related macular degeneration, and rare genetic disorders like achondroplasia.

Recent filings

Filing Released Lang Actions
半期報告書－第22期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-annual Report) for RIBOMIC Inc., covering the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements, management analysis of business conditions, and operational updates. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2024-11-13 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, following resolutions made at the company's 21st Annual General Meeting (AGM) held on June 25, 2024. Section 2 details the resolutions passed, specifically concerning the election of directors and the revision of remuneration for directors and auditors. This content—reporting the results of a shareholder meeting—perfectly matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to the AGM, the core purpose is reporting the *results* of the vote, not providing the meeting materials (AGM-R) or proxy information (PSI).
2024-06-26 Japanese
内部統制報告書－第21期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and the table. It cites the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法). It discusses the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of the fiscal year-end (March 31, 2024). This content directly corresponds to the requirements for an Audit Report/Information filing, specifically concerning internal controls, which aligns best with the 'Audit Report / Information (AR)' definition, as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2024-06-26 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document text contains Japanese characters and includes the title "有価証券報告書（通常方式）" which translates to "Securities Report (Normal Method)". It also explicitly mentions the submission date (2024年６月26日), the filing entity (株式会社リボミック), and confirms the appropriateness of the contents of the 21st period's Securities Report based on the Financial Instruments and Exchange Act. A Securities Report in the Japanese regulatory context is equivalent to the comprehensive annual filing, which corresponds to the US 10-K filing type. Although the document itself appears to be a confirmation statement ('確認書') related to the Securities Report, the core subject matter is the annual financial disclosure document (Securities Report). Given the options, the closest equivalent to a comprehensive annual report is '10-K'. The document length is very short (549 chars), suggesting it might be an accompanying confirmation or cover sheet, but the content directly references the full annual report ('有価証券報告書'). Since '10-K' represents the Annual Report, and this document confirms its accuracy, it is the most appropriate classification for the underlying subject matter, rather than a generic RPA or RNS. FY 2024
2024-06-26 Japanese
有価証券報告書－第21期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers the fiscal year from April 1, 2023, to March 31, 2024, and contains comprehensive financial statements, management discussion, and business information. This corresponds to the definition of an Annual Report (10-K) in the provided schema. FY 2024
2024-06-26 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies the period covered: "第21期第３四半期（自 2023年10月１日 至 2023年12月31日）". It also mentions confirmation by the Representative Director regarding the appropriateness of the filing based on the Financial Instruments and Exchange Act. This content strongly indicates a comprehensive financial report for an interim period shorter than a year. This aligns directly with the definition of an Interim / Quarterly Report (Code: IR). The document length is very short (547 chars), but the content is the substance of the confirmation regarding the quarterly report itself, not merely an announcement of its publication, thus classifying it as IR rather than RPA or RNS.
2024-02-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.